Real-World Evidence
FDA and Flatiron Health join forces to evaluate real-world outcomes in patients with organ impairment
In today's rapidly evolving landscape of accelerated drug development, reliance on data derived from traditional randomized control trials (RCTs) is shifting toward a combination of RCT data and real-world data (RWD) from sources like electronic health records (EHRs), health insurance claims, social determinants of health (SDoH), and patient surveys. A growing body of literature1 suggests RWD promises to advance our understanding of critical aspects within clinical pharmacology and ...